Gene Expression Analysis For Neuroscientists

In Vitro and In Vivo Studies

Neuromics has a strong line up of Transfection Tools designed specifically for Neuroscientists. Neurons, Glia and Astrocytes are notoriously hard to transfect. We are proud of our track record.

This is an excellent study for Neuroscience Researchers interested in using best methods: http://emboj.embopress.org/content/embojnl/31/15/3239/DC1/embed/inline-supplementary-material-1.pdf?download=true.  Here researchers delivered 14-3-3 siRNA sub units + i-Fect intrathecally. Here's specific knockdown results:

Figure: A. Dose-dependent inhibition of 14-3-3-zeta (z) expression with anti-14-3-3-z siRNA as measured with qRT-PCR in cultured spinal neurons (n = 3 independent experiments). B. Immunolabeling for 14-3-3-z is visualized in the dorsal horn of naive rats after intrathecal injection of mismatch RNA (a, mmRNA; 2 µg in 10µL i-Fect reagent) or anti-14-3-3-z siRNA (b, anti-14-3-3-z siRNA; 2 µg in 10µL i-Fect reagent). Bar: 50 µm C. Detection in the spinal cord (a, SC) and lumbar dorsal root ganglia (b, DRG) of intrathecally injected fluorescent siRNA. Staining is seen in the dorsal horn (open star) but not in the dorsal root ganglia (filled star). Bar: 50 µm D1. Quantification of 14-3-3-z mRNA levels with qRT-PCR in the ipsilateral lumbar (L4 and L5) dorsal spinal cord of three groups of rats (n=4 in each group): sham, neuropathic (same data as Figure 1B), and neuropathic with 3 intrathecal injections of anti-14-3-3-z siRNA. The upregulation of 14-3-3 mRNA in neuropathic conditions is abolished after anti-14-3-3-z siRNA injections. D2. Same quantitative procedure carried out in the ipsilateral lumbar (L4 and L5) dorsal root ganglia. No modification was induced by intrathecal injections of anti-14-3-3-z siRNA (n=4 in each group, same data as Figure S1B for Sham and SNL).

Our customers have successfully studied many genes with our tools. Here's a sampling: ABCA, ASIC, β-arrestin, CAV, CX3CR1, DOR, ELOVL4, IKBKAP, K+-ATPase, K_V1.1, K_V9.1 ,The β3 subunit of the Na+,K+-ATPase, NTS1, NAV_1.8, NTS1, NOV, Raf-1, RANK, SNSR1, hTert,  NOV, Survivin, TLR4, Troy and  TRPV1. Here're the related publications.

intra-i-Fect and intravenous delivery of siRNA

Deliver siRNA in-vivo with stunning results! Introductory Special-200 to 600 USD (valid through 9/30/2010)
These intra-i-Fect kits are designed to deliver siRNA in vivo via intravenous injections with high efficiency to specific tissue in rats and mice. The protocol involves these simple steps: prep, mix, dry, hydrate and inject.

Figure: siRNAs knock down profiles of the gene related to cancer, diabetes, obesity, steatosis hepatitis, cirrhosis and a gene specifically expressed in endothelial cells in liver

They are developed using a proprietary platform that uses nano-particles as the delivery vehicle. This platform enables:
•Effective delivery (60%+ knockdown) with no toxicity.
•Scalable to high throughput siRNA based gene screening.
•Consistent and reproducible results.